BioLineRx to Present at the LD Micro Main Event
About BioLineRx
BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company
dedicated to identifying, in-licensing and developing promising
therapeutic candidates. The Company in-licenses novel compounds
primarily from academic institutions and biotech companies based in
BioLineRx’s current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for relapsed/refractory AML, has recently initiated a Phase 2b study as an AML consolidation treatment, has recently initiated a Phase 1/2 study in hMDS and AA, and has successfully completed a Phase 1 study in stem cell mobilization; and BL-7010 for celiac disease, which has successfully completed a Phase 1/2 study.
In
For more information on BioLineRx, please visit www.biolinerx.com
or download the investor relations mobile device app, which allows users
access to the Company’s
View source version on businesswire.com: http://www.businesswire.com/news/home/20151124005375/en/
Source:
PCG Advisory
Vivian Cervantes, 212-554-5482
Investor Relations
vivian@pcgadvisory.com
or
for
BioLineRx Ltd.
Tsipi Haitovsky, +972-3-624-0871
Public
Relations
tsipihai5@gmail.com